产品
编 号：F195422
分子式：C16H12FN5O
分子量：309.3
分子式：C16H12FN5O
分子量：309.3
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1627696-51-8
产品详情
生物活性：
LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer.
体内研究：
LY3177833 (Example 4; 10.4-31.2 mg/kg; oral gavage; twice a day; for 2 weeks; female athymic Balb/c nude mice with SW620 cells) treatment causes significant tumor regression in a dose-dependent manner. Also, no significant tumor growth is observed for 2 weeks after dosing cessation.Animal Model:Female athymic Balb/c nude mice (5-6 weeks old) with SW620 cells
Dosage:10.4 mg/kg, 20.8 mg/kg and 31.2 mg/kg
Administration:Oral gavage; twice a day for 2 weeks
Result:Showed dose dependent antitumor activity in SW620 mouse xenograft tumor model.
体外研究：
LY3177833 (10 μM; 4 days) increases SA-β-gal content in Hep3B cells.
LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer.
体内研究：
LY3177833 (Example 4; 10.4-31.2 mg/kg; oral gavage; twice a day; for 2 weeks; female athymic Balb/c nude mice with SW620 cells) treatment causes significant tumor regression in a dose-dependent manner. Also, no significant tumor growth is observed for 2 weeks after dosing cessation.Animal Model:Female athymic Balb/c nude mice (5-6 weeks old) with SW620 cells
Dosage:10.4 mg/kg, 20.8 mg/kg and 31.2 mg/kg
Administration:Oral gavage; twice a day for 2 weeks
Result:Showed dose dependent antitumor activity in SW620 mouse xenograft tumor model.
体外研究：
LY3177833 (10 μM; 4 days) increases SA-β-gal content in Hep3B cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备